Ramin Tehranchi
Soborg, Denmark
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Dasiglucagon Effects on QTc in Healthy Volunteers: A Randomized, Placebo-Controlled, Dose-Escalation, Double-Blind Study.
Journal: Current therapeutic research, clinical and experimental
Published: October 29, 2021
Immunogenicity of the Novel Glucagon Analogue Dasiglucagon: Results of a Dedicated Immunogenicity Trial in Type 1 Diabetes.
Journal: Diabetes technology & therapeutics
Published: July 12, 2021
Dasiglucagon, a next-generation glucagon analogue, for treatment of severe hypoglycaemia via an autoinjector device: Results of a phase 3, randomized, double-blind trial.
Journal: Diabetes, obesity & metabolism
Published: March 15, 2021
Dasiglucagon, a next-generation ready-to-use glucagon analog, for treatment of severe hypoglycemia in children and adolescents with type 1 diabetes: Results of a phase 3, randomized controlled trial.
Journal: Pediatric diabetes
Published: December 21, 2020
Dasiglucagon-A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia: Results of Phase 3 Randomized Double-Blind Clinical Trial.
Journal: Diabetes care
Published: December 09, 2020
Low-factor consumption for major surgery in haemophilia B with long-acting recombinant glycoPEGylated factor IX.
Journal: Haemophilia : the official journal of the World Federation of Hemophilia
Published: June 20, 2016
Pharmacokinetics of recombinant factor XIII at steady state in patients with congenital factor XIII A-subunit deficiency.
Journal: Journal of thrombosis and haemostasis : JTH
Published: January 10, 2014
Pharmacokinetics of recombinant factor XIII in young children with congenital FXIII deficiency and comparison with older patients.
Journal: Haemophilia : the official journal of the World Federation of Hemophilia
Published: June 07, 2013
Showing 1-10 of 10
Last Updated: 09/26/2026